MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech, Inc. (PMCB)

|||

Balance Sheets Overview

Current Ratio
4528.01%
Quick Ratio
4528.01%
Cash Ratio
2251.13%
Debt to Asset Ratio
25.18%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Investment in preferred stock q...
    • Warrant assets qcls - non curre...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Treasury stock, at cost, 15,270,...
    • Others
Balance Sheets
2026-04-30
2025-04-30
Cash and cash equivalents
18,603,899
15,172,163
Marketable equity securities
254,010
366,316
Dividends receivable
240,766
-
Investment in preferred stock qcls - current
18,225,000
-
Warrant asset qcls - current
0
2,917,000
Convertible note receivable femasys - current
0
3,696,000
Other assets
-
7,688
Prepaid expenses and other current assets
96,879
223,759
Investment in preferred stock tnf
-
22,474,000
Total current assets
37,420,554
22,375,238
Intangible assets
0
1,549,427
Investment in preferred stock qcls
0
-
Warrant assets qcls - non current
8,845,000
5,701,000
Warrant assets femasys
480,000
3,061,000
Convertible note receivable femasys - non current
-
0
Other assets
7,688
-
Total other assets
9,332,688
32,793,115
Total assets
46,753,242
55,168,353
Accounts payable
271,102
399,204
Accrued expenses
522,831
2,515,080
Accrued series c dividends
32,491
0
Total current liabilities
826,424
2,914,284
Long-term portion of accrued expenses
0
25,000
Warrant liability
10,068,000
338,000
Derivative liability
878,000
0
Total other liabilities
10,946,000
363,000
Total liabilities
11,772,424
3,277,284
Convertible preferred stock-Series BPreferred Stock
0
0
Convertible preferred stock-Series CPreferred Stock
1,268,892
-
Contingently redeemable warrants
417,000
-
Total temporary equity
1,685,892
-
Preferred stock value
0
0
Common stock, authorized 200,000,000 shares, 0.0001 par value 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of april 30, 2026 and april 30, 2025, respectively
2,602
2,167
Additional paid-in capital
182,716,275
181,489,647
Accumulated deficit
-104,393,614
-84,968,960
Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of april 30, 2026, and 2025, respectively
45,009,541
44,607,916
Accumulated other comprehensive loss
-20,796
-23,869
Total stockholders equity
33,294,926
51,891,069
Total liabilities, temporary equity and stockholders equity
46,753,242
55,168,353
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$18,603,899 (22.62%↑ Y/Y)Investment in preferredstock qcls - current$18,225,000 Marketable equitysecurities$254,010 (-30.66%↓ Y/Y)Dividends receivable$240,766 Prepaid expenses andother current assets$96,879 (-56.70%↓ Y/Y)Warrant assets qcls - noncurrent$8,845,000 (55.15%↑ Y/Y)Warrant assets femasys$480,000 (-84.32%↓ Y/Y)Other assets$7,688 (0.00%↑ Y/Y)Total current assets$37,420,554 (67.24%↑ Y/Y)Total other assets$9,332,688 (-71.54%↓ Y/Y)Total assets$46,753,242 (-15.25%↓ Y/Y)Total liabilities,temporary equity and...$46,753,242 (-15.25%↓ Y/Y)Total stockholdersequity$33,294,926 (-35.84%↓ Y/Y)Total liabilities$11,772,424 (259.21%↑ Y/Y)Total temporaryequity$1,685,892 Accumulated deficit-$104,393,614 (-22.86%↓ Y/Y)Treasury stock, at cost,15,270,066 and 14,876,316...$45,009,541 (0.90%↑ Y/Y)Accumulated othercomprehensive loss-$20,796 (12.87%↑ Y/Y)Additional paid-in capital$182,716,275 (0.68%↑ Y/Y)Total otherliabilities$10,946,000 (2915.43%↑ Y/Y)Total currentliabilities$826,424 (-71.64%↓ Y/Y)Convertible preferredstock-Series CPreferred...$1,268,892 Contingently redeemablewarrants$417,000 Common stock,authorized 200,000,000...$2,602 (20.07%↑ Y/Y)Warrant liability$10,068,000 (2878.70%↑ Y/Y)Derivative liability$878,000 Accrued expenses$522,831 (-79.21%↓ Y/Y)Accounts payable$271,102 (-32.09%↓ Y/Y)Accrued series cdividends$32,491